SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Lease, Cost
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Lease, Cost of $33.28 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for the quarter ending 2026-06-30 was $33.28K, a 4.02% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for the quarter ending 2026-03-31 was $39.28K, a 16.14% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for the quarter ending 2025-12-31 was $60.37K, a 80.82% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for the quarter ending 2025-09-30 was $33.83K, a 8.33% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for fiscal 2025 was $160.02K, a 26.44% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for fiscal 2024 was $126.56K, a 1.46% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for fiscal 2023 was $128.43K, a 103.51% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. lease, cost for fiscal 2022 was $63.10K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $33.28K 10-Q · filed 2026-09-24 | $72.57K 10-Q · filed 2026-09-24 | $132.94K derived: sum of 3 quarters · filed 2026-09-24 | $166.76K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | $39.28K 10-Q · filed 2026-05-15 | $99.65K derived: sum of 2 quarters · filed 2026-05-15 | $133.48K derived: sum of 3 quarters · filed 2026-05-15 | $165.48K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | $60.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $94.19K derived: sum of 2 quarters · filed 2026-03-31 | $126.19K derived: sum of 3 quarters · filed 2026-09-24 | $160.02K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $33.83K 10-Q · filed 2025-11-13 | $65.82K derived: sum of 2 quarters · filed 2026-09-24 | $99.65K 10-Q · filed 2025-11-13 | $133.03K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $32.00K 10-Q · filed 2026-09-24 | $65.82K 10-Q · filed 2026-09-24 | $99.21K derived: sum of 3 quarters · filed 2026-09-24 | $130.43K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $33.83K 10-Q · filed 2026-05-15 | $67.21K derived: sum of 2 quarters · filed 2026-05-15 | $98.44K derived: sum of 3 quarters · filed 2026-05-15 | $129.16K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $33.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $64.61K derived: sum of 2 quarters · filed 2026-03-31 | $95.33K derived: sum of 3 quarters · filed 2026-03-31 | $126.56K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $31.22K 10-Q · filed 2025-11-13 | $61.95K derived: sum of 2 quarters · filed 2025-11-13 | $93.17K 10-Q · filed 2025-11-13 | $131.02K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $30.72K 10-Q · filed 2025-08-13 | $61.95K 10-Q · filed 2025-08-13 | $99.79K derived: sum of 3 quarters · filed 2025-08-13 | $148.56K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $31.22K 10-Q · filed 2025-05-08 | $69.07K derived: sum of 2 quarters · filed 2025-05-08 | $117.84K derived: sum of 3 quarters · filed 2025-05-08 | $140.91K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $37.85K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $86.61K derived: sum of 2 quarters · filed 2025-02-26 | $109.69K derived: sum of 3 quarters · filed 2025-02-26 | $128.43K 10-K · filed 2025-02-26 | |
| 2023-09-30 | $48.76K 10-Q · filed 2024-11-13 | $71.84K derived: sum of 2 quarters · filed 2024-11-13 | $90.58K 10-Q · filed 2024-11-13 | $76.85K 10-Q · filed 2023-11-13 | $102.68K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $23.07K 10-Q · filed 2024-09-04 | $38.49K 10-Q · filed 2024-09-04 | $53.92K derived: sum of 3 quarters · filed 2024-09-04 | $68.63K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $15.42K 10-Q/A · filed 2024-09-04 | $30.85K derived: sum of 2 quarters · filed 2024-09-04 | $45.56K derived: sum of 3 quarters · filed 2024-09-04 | ||
| 2022-12-31 | $15.42K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $30.14K derived: sum of 2 quarters · filed 2024-09-04 | $63.10K 10-K/A · filed 2024-09-04 | ||
| 2022-09-30 | $14.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $47.68K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $32.97K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |